

LCAT3, a novel m6A-regulated long non-coding RNA, pl
via binding with FUBP1 to activate c-MYC

Journal of Hematology and Oncology

14, 112

DOI: [10.1186/s13045-021-01123-0](https://doi.org/10.1186/s13045-021-01123-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cross-Talk between Oxidative Stress and m6A RNA Methylation in Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-26.	1.9	26
2	N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target. <i>Frontiers in Immunology</i> , 2021, 12, 697026.	2.2	14
3	Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. <i>Bioengineered</i> , 2022, 13, 3108-3121.	1.4	20
4	The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role. <i>Molecular Cancer</i> , 2022, 21, 30.	7.9	26
5	The essential roles of m6A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 36.	3.5	38
6	METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m6A-dependent manner. <i>Cell Biology and Toxicology</i> , 2023, 39, 2033-2050.	2.4	11
7	The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m ⁶ A readers in cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 2744-2758.	2.6	30
8	m6A modification: recent advances, anticancer targeted drug discovery and beyond. <i>Molecular Cancer</i> , 2022, 21, 52.	7.9	138
9	Pan-Cancer Transcriptome and Immune Infiltration Analyses Reveal the Oncogenic Role of Far Upstream Element-Binding Protein 1 (FUBP1). <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 794715.	1.6	0
10	m ⁶ A-mediated regulation of PBX1-GCH1 axis promotes gastric cancer proliferation and metastasis by elevating tetrahydrobiopterin levels. <i>Cancer Communications</i> , 2022, 42, 327-344.	3.7	18
11	The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance. <i>Frontiers in Pharmacology</i> , 2022, 13, 873030.	1.6	8
12	The emerging roles of the interaction between m6A modification and c-Myc in driving tumorigenesis and development. <i>Journal of Cellular Physiology</i> , 2022, 237, 2758-2769.	2.0	6
13	LncRNA MNX1-AS1: A novel oncogenic propellant in cancers. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112801.	2.5	7
14	Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation. <i>Pathology Research and Practice</i> , 2022, 233, 153851.	1.0	15
15	The Establishment and Experimental Verification of an lncRNA-Derived CD8+ T Cell Infiltration ceRNA Network in Colorectal Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210922.	0.6	4
16	Prognostic Value of Drug Targets Predicted Using Deep Bioinformatic Analysis of m6A-Associated lncRNA-Based Pancreatic Cancer Model Characteristics and Its Tumour Microenvironment. <i>Frontiers in Genetics</i> , 2022, 13, 853471.	1.1	7
17	Overexpression of lncRNA-Gm2044 in spermatogonia impairs spermatogenesis in partial seminiferous tubules. <i>Poultry Science</i> , 2022, 101, 101930.	1.5	4
18	LncRNAs and CircRNAs in cancer. <i>MedComm</i> , 2022, 3, e141.	3.1	18

#	ARTICLE	IF	CITATIONS
19	Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches. <i>Seminars in Cancer Biology</i> , 2022, 86, 325-345.	4.3	35
20	The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	17
21	Development and Validation of Prognostic Model for Lung Adenocarcinoma Patients Based on m6A Methylation Related Transcriptomics. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
22	LINC00665/miRNAs axis-mediated collagen type XI alpha 1 correlates with immune infiltration and malignant phenotypes in lung adenocarcinoma. <i>Open Medicine (Poland)</i> , 2022, 17, 1259-1274.	0.6	0
23	The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	9
24	Identification and functional analysis of ^{N6} methyladenine (^{m6A}) related lncRNA across 33 cancer types. <i>Cancer Medicine</i> , 2023, 12, 2104-2116.	1.3	3
25	Crosstalk of Eight Types of RNA Modification Regulators Defines Tumor Microenvironments, Cancer Hallmarks, and Prognosis of Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	7
26	The pivotal regulatory factor circBRWD1 inhibits arsenic exposure-induced lung cancer occurrence by binding mRNA and regulating its stability. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 399-412.	2.0	6
27	A Novel m6A-Related lncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma. <i>Cells</i> , 2022, 11, 2399.	1.8	6
28	m ⁶ A-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism. <i>Theranostics</i> , 2022, 12, 6291-6307.	4.6	16
30	The role of non-coding RNA in tumorigenesis, development, diagnosis and treatment. <i>Scientia Sinica Vitae</i> , 2022, 52, 1796-1806.	0.1	1
31	The effects of epigenetic modifications on bone remodeling in age-related osteoporosis. <i>Connective Tissue Research</i> , 0, , 1-12.	1.1	0
32	Novel insight into the functions of N ⁶ methyladenosine modified lncRNAs in cancers (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	6
33	RNA m ⁶ A methylation in cancer. <i>Molecular Oncology</i> , 2023, 17, 195-229.	2.1	10
34	Emerging role of lncRNAs in osteoarthritis: An updated review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
35	LCAT1 is an oncogenic lncRNA by stabilizing the IGF2BP2-CDC6 axis. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
36	N6-methyladenosine Modification of Noncoding RNAs: Mechanisms and Clinical Applications in Cancer. <i>Diagnostics</i> , 2022, 12, 2996.	1.3	1
37	Long noncoding RNA study: Genome-wide approaches. <i>Genes and Diseases</i> , 2023, 10, 2491-2510.	1.5	2

#	ARTICLE	IF	CITATIONS
38	Expression patterns of platinum resistance-related genes in lung adenocarcinoma and related clinical value models. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
39	USF1-CHCHD4 axis promotes lung adenocarcinoma progression partially via activating the MYC pathway. <i>Discover Oncology</i> , 2022, 13, .	0.8	4
40	Methyltransferase-like 3 suppresses phenotypic switching of vascular smooth muscle cells by activating autophagosome formation. <i>Cell Proliferation</i> , 2023, 56, .	2.4	7
42	Construction and comprehensive analysis of a cuproptosis-related lncRNA signature for predicting prognosis and immune response in cervical cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
43	Novel insights into the interplay between m6A modification and programmed cell death in cancer. <i>International Journal of Biological Sciences</i> , 2023, 19, 1748-1763.	2.6	4
44	METTL3 activates PERK-eIF2 γ dependent coelomocyte apoptosis by targeting the endoplasmic reticulum degradation-related protein SEL1L in echinoderms. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2023, 1866, 194927.	0.9	0
45	The chromatin-associated RNAs in gene regulation and cancer. <i>Molecular Cancer</i> , 2023, 22, .	7.9	11
46	A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2023, 12, 230-246.	1.3	5
47	The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications. <i>Experimental and Molecular Medicine</i> , 2023, 55, 487-501.	3.2	5
48	The role of selected non-coding RNAs in the biology of non-small cell lung cancer. <i>Advances in Medical Sciences</i> , 2023, 68, 121-137.	0.9	9
49	Long noncoding RNA SNHG15: A promising target in human cancers. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
50	The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy. <i>British Journal of Cancer</i> , 2023, 129, 8-23.	2.9	6
51	Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma. <i>Medicine (United States)</i> , 2023, 102, e33530.	0.4	0
52	Gain-of-Function Variomics and Multi-omics Network Biology for Precision Medicine. <i>Methods in Molecular Biology</i> , 2023, , 357-372.	0.4	0
64	N6-methyladenosine RNA modifications: a potential therapeutic target for AML. <i>Annals of Hematology</i> , 0, , .	0.8	0
80	Emerging role of RNA modification and long noncoding RNA interaction in cancer. <i>Cancer Gene Therapy</i> , 0, , .	2.2	0